(NASDAQ: PRTA) Prothena Public Co's forecast annual revenue growth rate of 180.49% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.97%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.99%.
Prothena Public Co's revenue in 2025 is $10,341,000.On average, 5 Wall Street analysts forecast PRTA's revenue for 2025 to be $1,845,614,763, with the lowest PRTA revenue forecast at $150,723,950, and the highest PRTA revenue forecast at $4,427,516,020. On average, 4 Wall Street analysts forecast PRTA's revenue for 2026 to be $7,385,742,680, with the lowest PRTA revenue forecast at $741,238,852, and the highest PRTA revenue forecast at $13,726,645,410.
In 2027, PRTA is forecast to generate $12,017,005,182 in revenue, with the lowest revenue forecast at $5,921,298,020 and the highest revenue forecast at $18,112,712,343.